

Susan M Ott

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9173937/susan-m-ott-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

10,245
citations

19
h-index

49
g-index

49
ext. papers

11,041
ext. citations

7.5
avg, IF

5.56
L-index

#	Paper	IF	Citations
46	Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , 1987 , 2, 595-610	6.3	4132
45	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. <i>Lancet, The</i> , 1996 , 348, 1535-41	40	3001
44	Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2-17	6.3	1588
43	The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. <i>New England Journal of Medicine</i> , 1982 , 307, 709-13	59.2	314
42	Incidence of atypical nontraumatic diaphyseal fractures of the femur. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2544-50	6.3	290
41	Mineral changes in osteoporosis: a review. <i>Clinical Orthopaedics and Related Research</i> , 2006 , 443, 28-38	2.2	111
40	Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 341-8	6.3	87
39	Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 415-21	6.3	82
38	Bone structure in patients with low bone mineral density with or without vertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2000 , 15, 1368-75	6.3	81
37	When bone mass fails to predict bone failure. <i>Calcified Tissue International</i> , 1993 , 53 Suppl 1, S7-13	3.9	75
36	Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. <i>Journal of the American Geriatrics Society</i> , 2008 , 56, 1434-41	5.6	61
35	Histomorphometric measurements of bone turnover, mineralization, and volume. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3 Suppl 3, S151-6	6.9	47
34	What is the optimal duration of bisphosphonate therapy?. <i>Cleveland Clinic Journal of Medicine</i> , 2011 , 78, 619-30	2.8	42
33	Therapy for patients with CKD and low bone mineral density. <i>Nature Reviews Nephrology</i> , 2013 , 9, 681-92	14.9	27
32	Bisphosphonate safety and efficacy in chronic kidney disease. <i>Kidney International</i> , 2012 , 82, 833-5	9.9	22
31	D-lactate and metabolic bone disease in patients receiving long-term parenteral nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 1989 , 13, 132-5	4.2	21
30	Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD. <i>Kidney International</i> , 2014 , 85, 1283-9	9.9	20

29	Histomorphometric Analysis of Bone Remodeling 2002 , 303-319		20
28	Bone strength: more than just bone density. <i>Kidney International</i> , 2016 , 89, 16-9	9.9	16
27	Clinical effects of bisphosphonates in involutional osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1993 , 8 Suppl 2, S597-606	6.3	16
26	Methods of determining bone mass. <i>Journal of Bone and Mineral Research</i> , 1991 , 6 Suppl 2, S71-6; discussion S83-4	6.3	15
25	Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2015 , 28, 363-9	2.5	13
24	Navel jewelry artifacts and intravertebral variation in spine bone densitometry in adolescents and young women. <i>Journal of Clinical Densitometry</i> , 2009 , 12, 84-8	3.5	11
23	Renal Osteodystrophy-Time for Common Nomenclature. <i>Current Osteoporosis Reports</i> , 2017 , 15, 187-193	3.4	10
22	Bone disease in CKD. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 376-81	3.5	10
21	Bone cells, sclerostin, and FGF23: what's bred in the bone will come out in the flesh. <i>Kidney International</i> , 2015 , 87, 499-501	9.9	9
20	Bone formation periods studied with triple tetracycline labels in women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1993 , 8, 443-50	6.3	9
19	Role of proton receptor OGR1 in bone response to metabolic acidosis?. <i>Kidney International</i> , 2016 , 89, 529-31	9.9	8
18	Bones and the sex hormones. <i>Kidney International</i> , 2018 , 94, 239-242	9.9	6
17	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1784-1802	4.7	5
16	A comparison of self-reported oral contraceptive use and automated pharmacy data in perimenopausal and early postmenopausal women. <i>Annals of Epidemiology</i> , 2015 , 25, 55-9	6.4	4
15	Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. <i>JAMA Network Open</i> , 2020 , 3, e2025190	10.4	4
14	Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 719-723	1.9	3
13	What Are the Most Common Errors in the Management of Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , 2007 , 2, 145-146	2.5	2
12	Letter re: Alendronate in Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5508-5508	5.6	2

11	Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. <i>BMC Musculoskeletal Disorders</i> , 2020 , 21, 801	2.8	1
10	Determinants of Oral Bisphosphonate Use Beyond 5 Years. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 197-202	1.9	1
9	Debating the duration of bisphosphonate therapy. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2013 , 26, 64-5	0.8	1
8	Osteoporosis Associated with Chronic Kidney Disease 2013 , 1387-1424		1
7	Does Estrogen Play a Role in Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , 2007 , 8, 4-11	2.5	1
6	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. <i>Kidney International</i> , 2021 , 100, 502-505	9.9	1
5	Renal insufficiency and bone loss. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 394-399	5.3	0
4	Osteoporosis associated with chronic kidney disease 2021 , 1325-1380		0
3	Renal Osteodystrophy and Bone Biopsy. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020 , 19, 215-225		
2	Structural and Metabolic Assessment of Bone. <i>Handbook of Experimental Pharmacology</i> , 2020 , 262, 369-396		
1	Not etched in bone: the role of osteoclast proton-sensing receptors. <i>Kidney International</i> , 2021 , 99, 542-545		